ConductScience.org, home

Paper40769005

Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy.

Song F and 7 others. Drug Resist Updat, 2025. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy. Papers, record 40769005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40769005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy.
PubMed
Journal
Drug Resist Updat
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
3.57, provisional
iCite
Revised in PubMed
2025-09-16
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Song FFeifeng
2Lin SSisi
3Xu TTong
4Yang CChang
5Sharavyn BBold
6Naranmandura HHua
7Zhang YYiwen
8Huang PPing

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
Drug Resistance, NeoplasmMajor topic
Molecular Targeted TherapyMajor topic
Antineoplastic AgentsMajor topic
Humans
Tumor Microenvironment
Signal Transduction
Mutation
Antineoplastic Combined Chemotherapy Protocols
Precision Medicine

Source PubMed

Download CSV of topics

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42941734Genetic and Immunologic Interactions Driving STAT3 Signaling and Macrophage Polarization in Acute Myeloid Leukemia.Int J Mol Sci2026https://conductscience.org/library/papers/42941734PubMed
42929838LEDGF/p75 Mediates Chemoresistance in Leukemia in a Context Dependent Manner.Cells2026https://conductscience.org/library/papers/42929838PubMed
42866821Mechanistic investigation of the crosstalk between hepatic ischemia-reperfusion injury and intestinal microbiota.Transl Gastroenterol Hepatol2026https://conductscience.org/library/papers/42866821PubMed
42496998Leveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges.Technol Cancer Res Treat2026https://conductscience.org/library/papers/42496998PubMed
42469871TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia.J Transl Med2026https://conductscience.org/library/papers/42469871PubMed
42452347Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.J Clin Med2026https://conductscience.org/library/papers/42452347PubMed
42201477Bioinformatics analysis and preliminary clinical validation of ITGA9 and NPTX2 as prognosis-related genes in acute myeloid leukemia.Discov Oncol2026https://conductscience.org/library/papers/42201477PubMed
42199454Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia.Blood Lymphat Cancer2026https://conductscience.org/library/papers/42199454PubMed
41786997From mechanism to clinic: a panoramic perspective on targeting HMOX1 to overcome drug resistance.J Cancer Res Clin Oncol2026https://conductscience.org/library/papers/41786997PubMed
41772642Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies.J Transl Med2026https://conductscience.org/library/papers/41772642PubMed
41754865Frontiers in Antibody-Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/41754865PubMed
41224963HPCAL1 as a novel prognostic biomarker in acute myeloid leukemia and its correlation with immune infiltrates.Sci Rep2025https://conductscience.org/library/papers/41224963PubMed
41104889Targeting cell death pathways in acute myeloid leukemia: Molecular mechanisms and clinical implications (Review).Oncol Rep2025https://conductscience.org/library/papers/41104889PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40769005

GET https://conductscience.org/api/papers/v1/40769005/authors